

Prescribing Clinical Network

Policy Statement	Oxycodone and Naloxone Combination Product
Policy Number	PCN 315-2018
Date of Issue	January - 2018
Review Date:	January - 2021 (Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)

Recommendations:

The Prescribing Clinical Network does not recommend the use of oxycodone and naloxone combination product

Oxycodone and Naloxone Combination Product will be considered **BLACK** on the traffic light system, prescribers should:

- NOT initiate oxycodone and naloxone combination product for any new patient AND
- De-prescribe oxycodone and naloxone combination product, with specialist support if appropriate, in all patients

In exceptional circumstances where there is a clinical need for oxycodone and naloxone combination product to be prescribed in primary care this should be undertaken in a cooperation arrangement with a multidisciplinary team and / or other healthcare professional

Key Considerations:

- NHS England guidance 'Items which should not routinely be prescribe in primary care: Guidance for CCGs' - https://www.england.nhs.uk/wp-content/uploads/2017/11/items-which-should-not-be-routinely-precscribed-in-pc-ccg-guidance.pdf
- PrescQIPP bulletin May 2014 issued a bulletin that did not identify a benefit of Oxycodone and Naloxone in a single product over other analgesia (with laxatives if necessary). https://www.prescqipp.info/-oxycodone/naloxone-prolonged-release-targinact-tablets/1307-bulletin-56-oxycodone-naloxone-prolonged-release
- The cost of the Oxycodone and Naloxone combination product is significant and the role of the combination product in therapy compared with individual products is unclear

Date taken to Prescribing Clinical Network	10 th January 2018
Agreed by PCN members	22 nd January 2018

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG